KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Cash from Investing Activities (2016 - 2025)

Jazz Pharmaceuticals has reported Cash from Investing Activities over the past 16 years, most recently at -$372.2 million for Q4 2025.

  • Quarterly results put Cash from Investing Activities at -$372.2 million for Q4 2025, down 92.54% from a year ago — trailing twelve months through Dec 2025 was -$1.5 billion (down 197.11% YoY), and the annual figure for FY2025 was -$1.5 billion, down 197.11%.
  • Cash from Investing Activities for Q4 2025 was -$372.2 million at Jazz Pharmaceuticals, down from -$327.8 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for JAZZ hit a ceiling of $737.1 million in Q1 2021 and a floor of -$5.9 billion in Q2 2021.
  • Median Cash from Investing Activities over the past 5 years was -$129.0 million (2022), compared with a mean of -$392.0 million.
  • Biggest five-year swings in Cash from Investing Activities: skyrocketed 1326.92% in 2021 and later tumbled 5538.82% in 2024.
  • Jazz Pharmaceuticals' Cash from Investing Activities stood at -$10.1 million in 2021, then tumbled by 3114.21% to -$324.4 million in 2022, then surged by 131.38% to $101.8 million in 2023, then crashed by 289.87% to -$193.3 million in 2024, then crashed by 92.54% to -$372.2 million in 2025.
  • The last three reported values for Cash from Investing Activities were -$372.2 million (Q4 2025), -$327.8 million (Q3 2025), and -$641.0 million (Q2 2025) per Business Quant data.